Kite Lake Sends Letter to Inmarsat Plc Board of Directors Following Letters From Oaktree and Rubric
5.11.2019 18:46:00 EET | Business Wire | Press release
Kite Lake Capital Management (UK) LLP which, as Investment Manager / Sub-Advisor for and on behalf of underlying funds, has an economic interest in 17,770,258 shares (over 3.8% of the outstanding equity) of Inmarsat Plc ("Inmarsat") has today announced that it has sent a letter to the Board of Directors of Inmarsat following earlier letters from Oaktree Capital Management, L.P. and Rubric Capital Management LP.
The full text of the letter is set out below.
The Board of Directors of Inmarsat Plc
99 City Road
London, EC1Y 1AX
UK
5 November 2019
To the Board of Directors of Inmarsat Plc:
Kite Lake Capital Management (UK) LLP (“Kite Lake”), as Investment Manager / Sub-Advisor for and on behalf of underlying funds, has an economic interest in 17,770,258 shares of Inmarsat Plc (over 3.8% of the outstanding equity).
Kite Lake notes the letter published by Oaktree Capital Management (“Oaktree”) on 5 November 2019, and we are in full agreement with the points Oaktree raises. This is an almost unprecedented situation, in which a spectrum asset (“Ligado”), appears to have been ascribed limited to zero value in the analysis of the fairness of the Consortium Scheme price. This is evidenced by the lack of any reference in the Scheme document to Ligado’s potential value, and on the 1Q 2019 Inmarsat Earnings Call held 1st May 2019: To quote CEO Rupert Pearce “… there will be no Ligado revenues in 2019 and we’re not planning for them to return to paying us, anytime in the near future.”
It has since been widely reported that Ligado could very well receive final regulatory approval imminently after over 10 years of delays. This approval is potentially only weeks away, and at the very minimum, we believe that the Board should delay the Scheme hearing until just prior to the Long Stop Date of 10 December 2019 to allow as much time as possible to clarify the regulatory position of Ligado to determine the best course of action with respect to Inmarsat’s current shareholders.
The question we pose to the Board is simple: given the material prospect of regulatory approval prior to the Long Stop Date, would the Board recommend a $7.09 offer if it was made today? We believe the answer should be a categorical no.
We also note the letter of today's date from Rubric Capital Management LP ("Rubric"). Like Rubric, in May 2019, Kite Lake voted for the Scheme, having moved shares owned into “cash” from “swap”, at the expense of the funds managed by Kite Lake at the request of Consortium advisors (on the basis that the vote was expected to be very close). We did so after several discussions with one of the Financial Advisors of the Consortium, with the understanding that if there was a material development with respect to Ligado prior to the Scheme Sanction, the Board would have the ability to either change its recommendation of the Scheme or delay the Scheme hearing.
We believe the Board must do the right thing for existing shareholders and delay the Scheme hearing as long as possible in order to clarify the current state of Ligado. We don’t see any disadvantage to existing shareholders in doing so. The shareholders deserve nothing less.
We note the announcement made by Inmarsat today. If the Board declines to engage with the Oaktree request, Kite Lake’s current intention is to attend the Scheme Hearing, and to indicate our concerns relating to the proposed transaction to the Court.
Sincerely,
Jamie Sherman
Partner
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191105005824/en/
Contact information
Jamie Sherman
+44 207 052 8310
jamie.sherman@kitelake.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 21:00:00 EET | Press release
Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham, MSc, MD, FRCPC, dermatologist, SKiN Centre for Dermatology, Peterborough, Ontario, Canada, principal investigator for the Latitude PsO studies and presenting author. “These efficacy and safety results show it’s possible for a once-daily pill to deliver rapid, lasting skin clearance, highlighting the potential of zasoc
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 21:00:00 EET | Press release
Incyte (Nasdaq:INCY) today announced 54-week data evaluating the safety and efficacy of povorcitinib (INCB54707), an oral small-molecule highly-selective JAK1 inhibitor, from the pivotal Phase 3 STOP-HS clinical trial program in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS). The late-breaking oral presentation of these data is taking place at the 2026 American Academy of Dermatology (AAD) Annual Meeting, being held March 27-31, 2026, in Denver (Session: S034 – Late-Breaking Research: Session 2. Saturday, March 28, 2026, 1:00-4:00 p.m. MT). “The 54-week results from the STOP-HS program deliver compelling, long-term evidence supporting the potential of povorcitinib for patients with moderate to severe HS,” said Pablo J. Cagnoni, M.D., President and Global Head of Research and Development, Incyte. “Across both studies, povorcitinib demonstrated substantial and durable improvements over time in key measures of treatment success and meaningful clinical ben
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 17:00:00 EET | Press release
Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-breaking session at the 2026 American Academy of Dermatology (AAD) Annual Meeting. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260328320362/en/ Atopic dermatitis is the most common inflammatory skin disorder in children, yet treatment options in the moderate-to-severe pediatric setting are limited.5 The disease can have a significant impact on quality of life for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school and relationships.5-8 “Atopic dermatitis can affect many aspects of children’s lives including schoolwork, emotional development
Angelalign Technology (6699.HK) Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 21:56:00 EET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 19:46:00 EET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
